Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy

Trial Profile

Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FIT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2016 Status changed from recruiting to discontinued as acrrual target was not being met.
    • 26 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top